Crescent Biopharma (CBIO) Interest Expenses (2024 - 2025)

Crescent Biopharma (CBIO) reported Interest Expenses of $1.1 million for Q2 2025, down 3.51% quarter-over-quarter from $1.1 million in Q1 2025.

Crescent Biopharma (CBIO) Interest Expenses (2024 - 2025) Analysis & Trends

Crescent Biopharma (CBIO) has 2 years of Interest Expenses data on file, last reported at $1.1 million in Q2 2025.

Interest Expenses for Q2 2025 came in at $1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 45.37% YoY), and the FY2025 annual result was $2.2 million, changed N/A from the prior year.
Interest Expenses declined to $1.1 million in Q2 2025 per CBIO's latest filing, from $1.1 million in the prior quarter.
Over five years, Interest Expenses peaked at $1.1 million in Q1 2025 and troughed at $852000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int Expense (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-5.50 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-332,000.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	61,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-2,753.00
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-5.58 Mn
10	Crescent Biopharma	486.92 Mn	297.76 Mn	-	-

Download Data